Result of General Meeting

RNS Number : 0863U

Redx Pharma plc

04 April 2016

 

4 April 2016

REDX PHARMA PLC

("Redx" or "the Company")

Grant of options

Redx, the drug discovery and development company, announces that on 4 April 2016 options over 52,941 ordinary shares of 1p each in the share capital of Company, were granted to Philip Tottey, Chief Financial Officer under Redx's Enterprise Management Incentive Scheme. The options are exercisable at a price of 42.5p, with two-thirds of the options being exercisable immediately and one-third of the shares becoming exercisable on 27 March 2017.

For further information please contact:

Redx Pharma Plc	T: 0151 706 4747
Neil Murray, Chief Executive Company website: redxpharma.com
Cantor Fitzgerald Europe (Nomad & Broker)	T: 020 7894 7000
Phil Davies / Michael Reynolds
KTZ Communications	T: 020 3178 6378
Katie Tzouliadis/ Viktoria Langley/ Emma Pearson

About Redx Pharma Plc

 www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary (patent‑protected) drug programs. Six proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.

 

END

 

 

ROMIIMBTMBAMBPF